Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Myriad Genetics (MYGN) Interest Expenses (2016 - 2026)

Myriad Genetics has reported Interest Expenses over the past 16 years, most recently at $4.4 million for Q4 2025.

  • Quarterly Interest Expenses rose 528.57% to $4.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.5 million through Dec 2025, up 275.0% year-over-year, with the annual reading at $10.5 million for FY2025, 275.0% up from the prior year.
  • Interest Expenses was $4.4 million for Q4 2025 at Myriad Genetics, up from $3.8 million in the prior quarter.
  • Over five years, Interest Expenses peaked at $4.4 million in Q4 2025 and troughed at $500000.0 in Q4 2021.
  • The 5-year median for Interest Expenses is $850000.0 (2022), against an average of $1.3 million.
  • Year-over-year, Interest Expenses crashed 91.38% in 2021 and then skyrocketed 528.57% in 2025.
  • A 5-year view of Interest Expenses shows it stood at $500000.0 in 2021, then surged by 80.0% to $900000.0 in 2022, then changed by 0.0% to $900000.0 in 2023, then dropped by 22.22% to $700000.0 in 2024, then skyrocketed by 528.57% to $4.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Interest Expenses are $4.4 million (Q4 2025), $3.8 million (Q3 2025), and $1.5 million (Q2 2025).